Literature DB >> 11893686

Giles F. Filley Lecture. Genetics and gene expression in lymphangioleiomyomatosis.

Gustavo Pacheco-Rodriguez1, Arnold S Kristof, Linda A Stevens, Yi Zhang, Denise Crooks, Joel Moss.   

Abstract

Lymphangioleiomyomatosis (LAM) is a disease of unknown etiology that is characterized by the proliferation of abnormal smooth muscle cells (LAM cells) in the lung, which leads to cystic parenchymal destruction and progressive respiratory failure. Recent evidence suggests that the proliferative and invasive nature of LAM cells may be due, in part, to somatic mutations in the TSC2 gene, which has been implicated in the pathogenesis of tuberous sclerosis complex. Here, we describe the clinical and molecular characteristics of LAM, as well as the efforts now under way to understand the genetic and biochemical factors that lead to progressive pulmonary destruction and, ultimately, to lung transplantation or death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893686     DOI: 10.1378/chest.121.3_suppl.56s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis.

Authors:  Hannah Peavy; Dorothy Gail; James Kiley; Susan Shurin
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

Review 2.  mTOR signaling in lymphangioleiomyomatosis.

Authors:  Arnold S Kristof
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

3.  Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis.

Authors:  Julio C Valencia; Gustavo Pacheco-Rodriguez; Adriana K Carmona; Janina Xavier; Patrick Bruneval; William K Riemenschneider; Yoshihiko Ikeda; Zu-Xi Yu; Victor J Ferrans; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2006-02-10       Impact factor: 6.914

4.  Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.

Authors:  Carolina Salim Gonçalves Freitas; Bruno Guedes Baldi; Mariana Sponholz Araújo; Glaucia Itamaro Heiden; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2015 May-Jun       Impact factor: 2.624

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.